# Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy

> **NCT01679197** · PHASE2 · COMPLETED · sponsor: **University of Michigan** · enrollment: 23 (actual)

## Conditions studied

- Fatty Liver Disease, Nonalcoholic
- Nonalcoholic Steatohepatitis
- Lipodystrophy

## Interventions

- **DRUG:** Metreleptin

## Key facts

- **NCT ID:** NCT01679197
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-08
- **Primary completion:** 2016-07-13
- **Final completion:** 2016-07-13
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01679197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01679197, "Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01679197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*